Ospemifene Side Effects
More frequently reported side effects include: endometrial hyperplasia and hot flash. See below for a comprehensive list of adverse effects.
For the Consumer
Applies to ospemifene: oral tablet
Along with its needed effects, ospemifene may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking ospemifene:
- chest pain
- difficulty with speaking
- dizziness or lightheadedness
- double vision
- fast heartbeat
- inability to move the arms, legs, or facial muscles
- inability to speak
- pain, redness, or swelling in the arm or leg
- slow speech
- sudden shortness of breath or troubled breathing
- Chest discomfort
- pain or discomfort in the arms, jaw, back, or neck
- shortness of breath
Some side effects of ospemifene may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Feeling of warmth
- increased sweating
- redness of the face, neck, arms, and occasionally, upper chest
- Muscle spasms
- white or brownish vaginal discharge
For Healthcare Professionals
Applies to ospemifene: oral tablet
The more commonly reported adverse events have included hot flush, vaginal discharge, muscle spasms, genital discharge, and hyperhidrosis.
In clinical trials, the incidence of DVT in women receiving this drug at 60 mg/day was 1.45 per thousand women compared with 1.04 per thousand women receiving placebo. In clinical trials of up to 15 months, the incidence rate of thromboembolic and hemorrhagic stroke were 0.72 and 1.45 per thousand women, respectively, compared with 1.04 and 0 per thousand women in placebo.
During clinical trials, one women receiving this drug had a myocardial infarction.
Common (1% to 10%): Hot flashes
Uncommon (0.1% to 1%): Hemorrhagic stroke, deep vein thrombosis (DVT)
Rare (less than 0.1%): Thromboembolic stroke, myocardial infarction[Ref]
Common (1% to 10%): Vaginal discharge, genital discharge, proliferative endometrium, endometrial thickening
Uncommon (0.1% to 1%): Uterine polyps
Rare (less than 0.1%): Simple hyperplasia without atypia[Ref]
During clinical trials, one case of simple hyperplasia without atypia occurred. Endometrial thickening of 5 mm or greater was observed in women taking 60 mg/day at a rate of 60.1 per thousand compared to 21.2 per thousand in the placebo group. Any type of proliferative (weakly plus active plus disordered) endometrium was reported at 86.1 per thousand in women taking this drug compared with 13.3 per thousand for placebo. Uterine polyps occurred at an incidence of 5.9 per thousand compared with 1.8 per thousand in those receiving this drug and placebo, respectively. Endometrial cancer was not reported in trials up to 52 weeks long.[Ref]
Common (1% to 10%): Hyperhidrosis
Common (1% to 10%): Muscle spasms[Ref]
Postmarketing reports: Allergic conditions including hypersensitivity, angioedema
1. "Product Information. Osphena (ospemifene)." Shionogi USA Inc, Florham Park, NJ.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
More about ospemifene
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 20 Reviews
- Drug class: selective estrogen receptor modulators
Other brands: Osphena